Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Phosphodiesterase 3 Inhibitor [EPC]

Known as: Phosphodiesterase 3 Inhibitor, Phosphodiesterase III Inhibitor 
National Institutes of Health

Related topics

Related topics

2 relations
Phosphodiesterase 3 InhibitorsPhosphodiesterase 3 Inhibitors [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Suppression of experimental atrial fibrillation in a canine model of rapid atrial pacing by the phosphodiesterase 3 inhibitor cilostazol.
OBJECTIVE Atrial fibrillation (AF) represents the most common arrhythmia encountered in cardiology department. The purpose of… Expand
2019
2019
Gastroprotective effect of cilostazol against ethanol- and pylorus ligation–induced gastric lesions in rats
Despite the availability of effective antiulcer medications, their suboptimal safety profile ignites the search for alternative… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
2019
2019
Role of Nrf2/HO-1 and PI3K/Akt Genes in the Hepatoprotective Effect of Cilostazol.
BACKGROUND Cilostazol, a phosphodiesterase 3 inhibitor (PDE3I), is a platelet aggregation inhibitor and vasodilator that is… Expand
Review
2016
Review
2016
Oral Enoximone as an Alternative to Protracted Intravenous Medication in Severe Pediatric Myocardial Failure
Phosphodiesterase 3 inhibitors have been used successfully in pediatric patients with acute or chronic myocardial dysfunction… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Review
2015
Review
2015
Effects of cilostazol on the progression and regression of symptomatic intracranial artery stenosis: it reduces the risk of ischemic stroke
OBJECTIVE: To assess the efficacy and safety of cilostazol on the progression and regression of symptomatic intracranial artery… Expand
  • figure 4
  • table 1
  • table 2
  • figure 2
  • figure 3
2014
2014
Effects of chronic treatment with cilostazol, a phosphodiesterase 3 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
OBJECTIVE To investigate whether bladder dysfunction after bladder outlet obstruction (BOO) could be altered by treatment with… Expand
  • figure 1
  • figure 2
  • figure 3
Review
2010
Review
2010
Dual antiplatelet therapy in the secondary prevention of atherothrombosis: need for new therapeutic approaches.
MOTS CLÉS Association d’antiagrégants plaquettaires ; Maladie thrombotique More than 22 million Americans are estimated to take… Expand
  • table 1
2008
2008
Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation.
BACKGROUND Cilostazol, a phosphodiesterase 3 inhibitor, is an antiplatelet drug that is widely used for preventing cardiovascular… Expand
Highly Cited
1999
Highly Cited
1999
Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients.
The effect of topical administration of phosphodiesterase (PDE) 3 inhibitors on the airway is not clear. In order to examine the… Expand
1996
1996
Effects of selective phosphodiesterase 3 inhibition in the perfused liver of the rat after endotoxin treatment
1 This study was designed to investigate the role of rat phosphodiesterase 3 (RPDE3) in regulation of liver metabolism in sepsis… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE